Yes, we are 10 days from the hockey stick curve gr
Post# of 148182
To the rest of the board, my apologies for not posting sooner (limited posts) and for not finding the GVHD trial. I mistakenly assumed I could search leronlimab and find them all, nope. Here is what I discovered, Leronlimab will get 3 hits, Cytodyn gets 14 hits, pro 140 gets 29 hits, and Vyrologix gets zero hits. Some think .gov is a waist of time, of course, I think those folks are defending the indefensible failures of the company to get it together. NP apparently would rather pump the story with $20k payments to proactive instead of tending the knitting and updated trials and getting press releases correct on basics like trial protocols requiring carbo in combo. They pay Amerex a lot of money for what? So the trials are not updated for months at a time? I am long about 1,200 shares of hard earned money and hoping to keep it at the very least...
I suspect we will see a deal overseas asap, compassionate use asap, IND confirmed asap, and the coup de grace will be a finance deal a few weeks after all that. BLA is a bid deal, the delays are very troubling. And the double blind placebo is a 2:1 ratio of leronlimab:placebo. This is rare and is only being used to help patients get the drug. It is harder on the company to prove efficacy. Unequal randomization (e.g. 2:1 or 3:1) is done quite rarely. There are some occasions when it is justified. Such a randomization needs to overcome scientific and ethical problems like ARDS lung damage if the patients don't get the drug.
Peace out